A carregar...
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Novel therapies are urgently needed to prevent and treat tyrosine kinase inhibitor resistance in chronic myeloid leukaemia (CML). MLN8237 is a novel Aurora A kinase inhibitor under investigation in multiple phase I and II studies. Here we report that MLN8237 possessed equipotent activity against Ba/...
Na minha lista:
| Publicado no: | J Cell Mol Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4394217/ https://ncbi.nlm.nih.gov/pubmed/21091633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2010.01218.x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|